Implementation opportunities for sodium-glucose Co-transporter-2 inhibitors in the Belgian heart failure landscape
- 22 July 2026
- journal article
- editorial
- Published by Taylor & Francis in Acta Cardiologica
- p. 1-2
Abstract
Heart failure (HF) remains a major public health challenge in Belgium and worldwide, associated with high morbidity and mortality. Recent advances in pharmacological therapy have significantly impr...Keywords
This publication has 15 references indexed in Scilit:
- Empagliflozin vs Dapagliflozin in Heart Failure: a Target Trial EmulationJournal of Cardiac Failure, 2025
- Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart FailureJAMA Network Open, 2024
- SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trialsThe Lancet, 2022
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart FailureJACC, 2022
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Journal of Heart Failure, 2022
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trialsThe Lancet, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015